blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2971077

EP2971077 - METHOD AND PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT AND PREDICTION OF MYOCARDIAL INFARCTION [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  27.03.2020
Database last updated on 09.09.2024
FormerThe patent has been granted
Status updated on  19.04.2019
FormerGrant of patent is intended
Status updated on  13.12.2018
FormerExamination is in progress
Status updated on  04.11.2016
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
INSERM (Institut National de la Santé et de la Recherche Médicale)
101, rue de Tolbiac
75013 Paris Cédex 13 / FR
For all designated states
Université Paris Descartes
12, rue de l'Ecole de Médecine
75006 Paris / FR
For all designated states
Sorbonne Université
21 rue de l'Ecole de Médecine
75006 Paris / FR
For all designated states
Assistance Publique-Hôpitaux de Paris (APHP)
3, avenue Victoria
75004 Paris / FR
[2019/21]
Former [2019/02]For all designated states
INSERM (Institut National de la Santé et de la Recherche Médicale)
101, rue de Tolbiac
75013 Paris Cédex 13 / FR
For all designated states
Université Paris Descartes
12, rue de l'Ecole de Médecine
75006 Paris / FR
For all designated states
Université Pierre et Marie Curie - UPMC
4 Place Jussieu
75005 Paris / FR
For all designated states
Assistance Publique-Hôpitaux de Paris (APHP)
3, avenue Victoria
75004 Paris / FR
Former [2016/03]For all designated states
INSERM - Institut National de la Santé et de la Recherche Médicale
101, rue de Tolbiac
75013 Paris / FR
For all designated states
Université Paris Descartes
12, rue de l'Ecole de Médecine
75006 Paris / FR
For all designated states
Université Pierre et Marie Curie
4, Place Jussieu
75005 Paris / FR
For all designated states
Assistance Publique-Hôpitaux de Paris (APHP)
3, avenue Victoria
75004 Paris / FR
Inventor(s)01 / MALLAT, Ziad
U970 - INSERM
GH Georges Pompidou Broussais
56 Rue Leblanc
F-75015 Paris / FR
02 / TEDGUI, Alain
U970 - INSERM
GH Georges Pompidou Broussais
56 Rue Leblanc
F-75015 Paris / FR
03 / SIMON, Tabassome
GU-HUEP
Hôpital St Antoine
184 rue du Fbg St Antoine
F-75012 Paris / FR
04 / DANCHIN, Nicolas
U970 - INSERM
GH Georges Pompidou Broussais
56 rue Leblanc
F-75015 Paris / FR
 [2016/03]
Representative(s)Inserm Transfert
PariSanté Campus
10 rue d'Oradour-sur-Glane
75015 Paris / FR
[N/P]
Former [2019/21]Inserm Transfert
7, rue Watt
75013 Paris / FR
Former [2016/03]Hirsch, Denise Marie
Inserm Transfert IP Department 7 rue Watt
75013 Paris / FR
Application number, filing date14710259.414.03.2014
[2016/03]
WO2014EP55059
Priority number, dateEP2013030529915.03.2013         Original published format: EP 13305299
[2016/03]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014140243
Date:18.09.2014
Language:EN
[2014/38]
Type: A1 Application with search report 
No.:EP2971077
Date:20.01.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 18.09.2014 takes the place of the publication of the European patent application.
[2016/03]
Type: B1 Patent specification 
No.:EP2971077
Date:22.05.2019
Language:EN
[2019/21]
Search report(s)International search report - published on:EP18.09.2014
ClassificationIPC:C12Q1/6883, C12Q1/68, C07K16/28
[2018/48]
CPC:
C07K16/2875 (EP,US); C07K16/2878 (US); C12Q1/6883 (EP,US);
G01N33/6872 (US); A61K2039/505 (EP,US); A61K39/3955 (US);
C07K14/525 (US); C07K2317/76 (EP,US); C12Q2600/118 (EP,US);
C12Q2600/158 (EP,US); G01N2333/70575 (US); G01N2800/324 (US);
G01N2800/52 (US); G01N33/53 (US) (-)
Former IPC [2016/03]C12Q1/68, C07K16/28
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/03]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:VERFAHREN UND PHARMAZEUTISCHE ZUSAMMENSETZUNG ZUR VERWENDUNG BEI DER BEHANDLUNG UND VORHERSAGE VON MYOKARDINFARKT[2016/03]
English:METHOD AND PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT AND PREDICTION OF MYOCARDIAL INFARCTION[2016/03]
French:PROCÉDÉ ET COMPOSITION PHARMACEUTIQUE POUR UNE UTILISATION DANS LE TRAITEMENT ET LA PRÉDICTION D'INFARCTUS DU MYOCARDE[2018/48]
Former [2016/03]PROCÉDÉ ET COMPOSITION PHARMACEUTIQUE DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT ET LA PRÉDICTION D'UN INFARCTUS DU MYOCARDE
Entry into regional phase01.09.2015National basic fee paid 
01.09.2015Designation fee(s) paid 
01.09.2015Examination fee paid 
Examination procedure01.09.2015Amendment by applicant (claims and/or description)
01.09.2015Examination requested  [2016/03]
25.10.2016Despatch of a communication from the examining division (Time limit: M06)
11.04.2017Reply to a communication from the examining division
12.06.2017Despatch of a communication from the examining division (Time limit: M06)
22.11.2017Reply to a communication from the examining division
26.03.2018Despatch of a communication from the examining division (Time limit: M03)
22.06.2018Reply to a communication from the examining division
14.12.2018Communication of intention to grant the patent
09.04.2019Fee for grant paid
09.04.2019Fee for publishing/printing paid
09.04.2019Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  25.10.2016
Opposition(s)25.02.2020No opposition filed within time limit [2020/18]
Fees paidRenewal fee
23.03.2016Renewal fee patent year 03
23.03.2017Renewal fee patent year 04
23.03.2018Renewal fee patent year 05
22.03.2019Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU14.03.2014
AL22.05.2019
AT22.05.2019
CY22.05.2019
CZ22.05.2019
DK22.05.2019
EE22.05.2019
FI22.05.2019
HR22.05.2019
LT22.05.2019
LV22.05.2019
MC22.05.2019
MK22.05.2019
MT22.05.2019
NL22.05.2019
PL22.05.2019
RO22.05.2019
RS22.05.2019
SE22.05.2019
SI22.05.2019
SK22.05.2019
SM22.05.2019
TR22.05.2019
BG22.08.2019
NO22.08.2019
GR23.08.2019
IS22.09.2019
PT22.09.2019
[2022/31]
Former [2022/30]HU14.03.2014
AL22.05.2019
AT22.05.2019
CY22.05.2019
CZ22.05.2019
DK22.05.2019
EE22.05.2019
FI22.05.2019
HR22.05.2019
LT22.05.2019
LV22.05.2019
MC22.05.2019
MT22.05.2019
NL22.05.2019
PL22.05.2019
RO22.05.2019
RS22.05.2019
SE22.05.2019
SI22.05.2019
SK22.05.2019
SM22.05.2019
TR22.05.2019
BG22.08.2019
NO22.08.2019
GR23.08.2019
IS22.09.2019
PT22.09.2019
Former [2022/27]HU14.03.2014
AL22.05.2019
AT22.05.2019
CY22.05.2019
CZ22.05.2019
DK22.05.2019
EE22.05.2019
FI22.05.2019
HR22.05.2019
LT22.05.2019
LV22.05.2019
MC22.05.2019
MT22.05.2019
NL22.05.2019
PL22.05.2019
RO22.05.2019
RS22.05.2019
SE22.05.2019
SI22.05.2019
SK22.05.2019
SM22.05.2019
TR22.05.2019
BG22.08.2019
NO22.08.2019
GR23.08.2019
PT22.09.2019
Former [2020/50]AL22.05.2019
AT22.05.2019
CZ22.05.2019
DK22.05.2019
EE22.05.2019
FI22.05.2019
HR22.05.2019
LT22.05.2019
LV22.05.2019
MC22.05.2019
NL22.05.2019
PL22.05.2019
RO22.05.2019
RS22.05.2019
SE22.05.2019
SI22.05.2019
SK22.05.2019
SM22.05.2019
TR22.05.2019
BG22.08.2019
NO22.08.2019
GR23.08.2019
PT22.09.2019
Former [2020/25]AL22.05.2019
AT22.05.2019
CZ22.05.2019
DK22.05.2019
EE22.05.2019
FI22.05.2019
HR22.05.2019
LT22.05.2019
LV22.05.2019
NL22.05.2019
PL22.05.2019
RO22.05.2019
RS22.05.2019
SE22.05.2019
SI22.05.2019
SK22.05.2019
SM22.05.2019
TR22.05.2019
BG22.08.2019
NO22.08.2019
GR23.08.2019
PT22.09.2019
Former [2020/17]AL22.05.2019
AT22.05.2019
CZ22.05.2019
DK22.05.2019
EE22.05.2019
FI22.05.2019
HR22.05.2019
LT22.05.2019
LV22.05.2019
NL22.05.2019
RO22.05.2019
RS22.05.2019
SE22.05.2019
SK22.05.2019
SM22.05.2019
TR22.05.2019
BG22.08.2019
NO22.08.2019
GR23.08.2019
PT22.09.2019
Former [2020/14]AL22.05.2019
AT22.05.2019
CZ22.05.2019
DK22.05.2019
EE22.05.2019
FI22.05.2019
HR22.05.2019
LT22.05.2019
LV22.05.2019
NL22.05.2019
RO22.05.2019
RS22.05.2019
SE22.05.2019
SK22.05.2019
SM22.05.2019
BG22.08.2019
NO22.08.2019
GR23.08.2019
PT22.09.2019
Former [2020/11]AL22.05.2019
AT22.05.2019
CZ22.05.2019
DK22.05.2019
EE22.05.2019
FI22.05.2019
HR22.05.2019
LT22.05.2019
LV22.05.2019
NL22.05.2019
RO22.05.2019
RS22.05.2019
SE22.05.2019
SK22.05.2019
BG22.08.2019
NO22.08.2019
GR23.08.2019
PT22.09.2019
Former [2020/10]AL22.05.2019
AT22.05.2019
CZ22.05.2019
DK22.05.2019
FI22.05.2019
HR22.05.2019
LT22.05.2019
LV22.05.2019
NL22.05.2019
RO22.05.2019
RS22.05.2019
SE22.05.2019
BG22.08.2019
NO22.08.2019
GR23.08.2019
PT22.09.2019
Former [2020/09]AL22.05.2019
CZ22.05.2019
DK22.05.2019
FI22.05.2019
HR22.05.2019
LT22.05.2019
LV22.05.2019
NL22.05.2019
RS22.05.2019
SE22.05.2019
BG22.08.2019
NO22.08.2019
GR23.08.2019
PT22.09.2019
Former [2019/51]AL22.05.2019
FI22.05.2019
HR22.05.2019
LT22.05.2019
LV22.05.2019
NL22.05.2019
RS22.05.2019
SE22.05.2019
BG22.08.2019
NO22.08.2019
GR23.08.2019
PT22.09.2019
Former [2019/50]AL22.05.2019
FI22.05.2019
HR22.05.2019
LT22.05.2019
LV22.05.2019
NL22.05.2019
RS22.05.2019
SE22.05.2019
NO22.08.2019
GR23.08.2019
PT22.09.2019
Former [2019/49]AL22.05.2019
FI22.05.2019
HR22.05.2019
LT22.05.2019
NL22.05.2019
SE22.05.2019
NO22.08.2019
PT22.09.2019
Former [2019/48]FI22.05.2019
LT22.05.2019
SE22.05.2019
NO22.08.2019
PT22.09.2019
Former [2019/47]FI22.05.2019
LT22.05.2019
NO22.08.2019
Cited inInternational search[X]WO0216411  (HUMAN GENOME SCIENCES INC [US]) [X] 4-8* page 95, line 22 - page 96, line 26 *;
 [X]US2003223996  (RUBEN STEVEN M [US], et al) [X] 4-8 * paragraph [0459] - paragraph [0460]; claims 1,76-79 *;
 [X]US2005048626  (DESJARLAIS JOHN R [US], et al) [X] 4-8 * paragraph [0225] *;
 [X]WO2005042009  (BIOGEN IDEC INC [US], et al) [X] 4-8 * example 3; claim 9 * * paragraph [0015] *;
 [XI]  - PHILIP KAHN ET AL, "Prevention of murine antiphospholipid syndrome by BAFF blockade", ARTHRITIS & RHEUMATISM, (20080901), vol. 58, no. 9, doi:10.1002/art.23764, ISSN 0004-3591, pages 2824 - 2834, XP055067459 [X] 4-8 * page 2824; figures 1,3 * [I] 1-3,9

DOI:   http://dx.doi.org/10.1002/art.23764
by applicantUS4816397
 US4946778
 US5225539
 WO9932619
 WO0043032
 WO0124811
 WO0136646
 WO0160397
 WO0168836
 WO02066516
 US6506559
 US6573099
 WO2004011611
 WO2004081043
 WO2006025345
 WO2006034106
 US7109304
 CN101851291
    - HOHEISEL, NATURE REVIEWS, GENETICS, (2006), vol. 7, pages 200 - 210
    - THOMAS D6MER; PETER E, "Lipsky, B-cell targeting: a novel approach to immune intervention today and tomorrow", EXPERT OPINION ON BIOLOGICAL THERAPY, (200709), vol. 7, no. 9, pages 1287 - 1299, XP009133112
    - LEONARD ET AL., CLINICAL CANCER RESEARCH, (2004), vol. 10, pages 53Z7 - 5334
    - DE BENEDETTI ET AL., J IMMUNOL, (2001), vol. 166, pages 4334 - 4340
    - SUZUKI ET AL., EUROP J OF IMMUNOL, (1992), vol. 22, no. 8, pages 1989 - 1993
    - AIT-OUFELLA, H. ET AL., "B cell depletion reduces the development of atherosclerosis in mice", J EXP MED, (2010), vol. 207, pages 1579 - 1587
    - ARMSTRONG, P.W. ET AL., "Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial", JAMA, (2007), vol. 297, pages 43 - 51
    - BUSCHE, M.N.; PAVLOV, V.; TAKAHASHI, K.; STAHL, G.L., "Myocardial ischemia and reperfusion injury is dependent on both IgM and mannose-binding lectin", AM J PHYSIOL HEART CIRC PHYSIOL, (2009), vol. 297, pages H1853 - 1859
    - CAZES, A. ET AL., "Mechanical ventricular assistance in heart failure: pathology of the cardiac apex removed during device implantation", CARDIOVASC PATHOL, (2010), vol. 19, pages 112 - 116, XP026878669
    - COCHAIN, C. ET AL., "Regulation of monocyte subset systemic levels by distinct chemokine receptors controls post-ischaemic neovascularization", CARDIOVASC RES, (2010), vol. 88, pages 186 - 195
    - EIKELBOOM, J.W.; O'DONNELL, M., "Pexelizumab does not ''complement'' percutaneous coronary intervention in patients with ST-elevation myocardial infarction", JAMA, (2007), vol. 297, pages 91 - 92
    - GRANGER, D.N.; KORTHUIS, R.J., "Physiologic mechanisms ofpostischemic tissue injury", ANNU REV PHYSIOL, (1995), vol. 57, pages 311 - 332
    - GRANGER, C.B. ET AL., "Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial", CIRCULATION, (2003), vol. 108, pages 1184 - 1190
    - GULLICK NICOLA; D'CRUZ DAVID, "New therapies for the treatment of systemic lupus erythematosus", EXPERT OPIN. THER. PATENTS, (2007), vol. 17, no. 3
    - HAAS, M.S. ET AL., "Blockade of self-reactive IgM significantly reduces injury in a murine model of acute myocardial infarction", CARDIOVASC RES, (2010), vol. 87, doi:doi:10.1093/CVR/CVQ141, pages 618 - 627, XP002698347

DOI:   http://dx.doi.org/10.1093/CVR/CVQ141
    - LEUSCHNER, F. ET AL., "Rapid monocyte kinetics in acute myocardial infarction are sustained by extramedullary monocytopoiesis", J EXP MED, (2012), vol. 209, pages 123 - 137
    - MAHAFFEY, K.W. ET AL., "Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial", CIRCULATION, (2003), vol. 108, pages 1176 - 1183
    - NAHRENDORF, M. ET AL., "The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions", J EXP MED, (2007), vol. 204, pages 3037 - 3047
    - SHAH, A.M.; MANN, D.L., "In search of new therapeutic targets and strategies for heart failure: recent advances in basic science", LANCET, (2011), vol. 378, pages 704 - 712
    - UCHIDA, J. ET AL., "Mouse CD20 expression and function", INT IMMUNOL, (2004), vol. 16, doi:doi:10.1093/intimm/dxh009, pages 119 - 129, XP003013383

DOI:   http://dx.doi.org/10.1093/intimm/dxh009
    - VINTEN-JOHANSEN, J., "Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury", CARDIOVASC RES, (2004), vol. 61, pages 481 - 497
    - WHITE, H.D.; CHEW, D.P., "Acute myocardial infarction", LANCET, (2008), vol. 372, pages 570 - 584
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.